Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma Foods International CoPMDSF 63 Debt-to-EBITDA is 8.25 as of Jan. 2026, which is 103% above its 10-year median of 4.07. GuruFocus rates PMDSF with a GF Score™ of 63/100 and a GF Value™ of $11.44. The stock has 5 warning signs investors should review. Among 689 Drug Manufacturers companies, Pharma Foods International Co ranks worse than 145137.74% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Pharma Foods International Co's Debt-to-EBITDA or its related term are showing as below:
PMDSF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -16.55 Med: 4.07 Max: 8.91
Current: -16.55
During the past 13 years, the highest Debt-to-EBITDA Ratio of Pharma Foods International Co was 8.91. The lowest was -16.55. And the median was 4.07.
PMDSF's Debt-to-EBITDA is ranked worse than 100% of 689
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs PMDSF: -16.55
Pharma Foods International Co (OTCPK:PMDSF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Pharma Foods International Co Debt-to-EBITDA Related Terms
Pharma Foods International Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Foods International Co Debt-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Pharma Foods International Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Foods International Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pharma Foods International Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pharma Foods International Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jan. 2026) EBITDA data.
Pharma Foods International Co (PMDSF) has a Debt-to-EBITDA of 8.25 as of Jan. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pharma Foods International Co. This is 103% above median its historical median of 4.07. According to the industry distribution chart, Pharma Foods International Co ranks #999999 out of 689 companies in the Drug Manufacturers industry.
Is Pharma Foods International Co's Debt-to-EBITDA too high?
Pharma Foods International Co's current Debt-to-EBITDA of 8.25 is 103% above median its 10-year median of 4.07. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Pharma Foods International Co's value of 8.25 is 391.1% above this industry median. Based on the distribution chart, Pharma Foods International Co ranks #999999 out of 689 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Pharma Foods International Co has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Pharma Foods International Co's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Pharma Foods International Co ranks #999999 out of 689 companies for Debt-to-EBITDA. This places Pharma Foods International Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. Pharma Foods International Co's value of 8.25 is 391.1% above this benchmark. While the company's 10-year median is 4.07 vs. the industry median of 1.68, Pharma Foods International Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Foods International Co's current Debt-to-EBITDA of 8.25 is 391.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pharma Foods International Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Foods International Co's current Debt-to-EBITDA is 8.25, which is 103% above median its own 10-year median of 4.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Foods International Co stock overvalued right now?
Pharma Foods International Co (PMDSF) has a current Debt-to-EBITDA of 8.25. The stock's GF Value™ is $11.44, compared to a current price of $6.40 — trading 44.1% below its estimated fair value. The current Debt-to-EBITDA is 8.25, which is 103% above median its 10-year median of 4.07 and 391.1% above the Drug Manufacturers industry median of 1.68. Pharma Foods International Co's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Pharma Foods International Co (PMDSF), the current Debt-to-EBITDA is 8.25 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Foods International Co (PMDSF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Foods International Co stock appears to be undervalued.
The current stock price of $6.40 is trading 44.1% below its estimated GF Value™ of $11.44.
Key valuation signals for PMDSF:
Debt-to-EBITDA: 8.25 (103% above median its 10-year median of 4.07)
GF Value™: $11.44 vs. price of $6.40 (44.1% below fair value)
Industry Position: 391.1% above the Drug Manufacturers median (#999999 of 689)
No single metric tells the full story. See the PMDSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Foods International Co Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMDSF has been successfully added to your 
